Biotechnology Sector

The timing of outpatient palliative care (PC) visits emerges as a crucial factor influencing healthcare utilization and decision-making for cancer patients approaching the end of life (EOL), according to a comprehensive retrospective cohort study published in BMC Cancer. This pioneering research, taking place at the Comprehensive Cancer Center Helsinki University Hospital, delved into the nuanced

In a groundbreaking study published in Nature Chemical Biology, researchers led by Lin, Ngo, and Chou have unveiled a novel approach to explore the intricate interactions within the microenvironment of ligand-activated epidermal growth factor receptor (EGFR) neighborhoods. This pioneering work showcases the development of a technique known as MultiMap, which leverages temporal photoproximity labeling. This

In an innovative study exploring the impact of animated storytelling on psychological resilience, researchers embarked on a randomized controlled trial aimed at understanding how short video interventions could shape psychological capital and related emotional states among adults in the United States. The concept of psychological capital, often abbreviated as PsyCap, encompasses four key components: hope,

In a groundbreaking study published in the Journal of Autism and Developmental Disorders, researchers A.D. Dueñas, L.R. Gómez, and M.R. Martin Loya delve into the often-overlooked realm of cultural adaptation practices within the autism service system. This mixed methods study sheds light on the nuances of how individuals from diverse cultural backgrounds navigate autism services,

In a groundbreaking advancement at the intersection of neuroscience, transplant biology, and bioimaging, researchers have developed a revolutionary method to achieve stable intracranial imaging of pancreatic islet cells engrafted in the dura mater of awake mice. This innovative technique represents a substantial leap forward in our ability to visualize and understand cellular dynamics in real-time

In a groundbreaking revelation concerning the intersection of radiology and oncology, a recent case report has positioned the apparent diffusion coefficient (ADC) as a promising radiological biomarker for detecting malignant transformation in retinoblastoma, one of the most aggressive eye cancers predominantly affecting children. This pioneering research, spearheaded by De Francesco et al., sheds light on

In a striking advancement poised to revolutionize biotechnological applications, researchers have unveiled a cutting-edge genetic engineering strategy that significantly boosts the secretion of recombinant proteins in a widely used model organism, Saccharomyces cerevisiae. This breakthrough, emerging from an elaborate understanding of cellular stress mechanisms, specifically addresses the molecular bottlenecks that previously limited protein production yields,

In a groundbreaking study, researchers have unveiled critical insights into familial hemophagocytic lymphohistiocytosis (HLH), a rare and severe immune disorder characterized by excessive activation of the immune system. The research, led by Alkaphoury, Mohammad, and Farghal, focuses on the clinical and neuroimaging features associated with this condition, providing a comprehensive overview that may significantly influence

In a landscape where pediatric healthcare innovation has long lagged behind adult medical advancements, a transformative framework has emerged to tackle this critical issue head-on. The System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) represents a concerted national effort to revolutionize the development and approval of pediatric-specific medical devices. Despite the pressing

In a significant advance that could redefine therapeutic strategies against breast cancer, researchers have unveiled a novel approach harnessing engineered natural killer cells to deliver microRNA molecules capable of halting cancer progression. This breakthrough centers on the exosomal transfer of miR-124 from genetically modified NK-92 cells, demonstrating potent anti-cancer effects by inhibiting tumor cell migration

In recent years, the quest for sustainable energy solutions has led to significant advancements in biogas production technologies. Among innovative methodologies, researchers have keenly explored the potential of anaerobic digestion of sewage sludge, a process capable of turning waste into valuable resources. Recent findings from Rühl and Engelhart shed light on a groundbreaking approach aimed

The recent narrative review conducted by DeLacey, Dieguez, and Bensignor delves into the intricate landscape of glycemic management in youth with Type 2 Diabetes (T2D), particularly emphasizing the roles of GLP-1 receptor agonists and SGLT-2 inhibitors. This examination arrives at a pivotal moment as childhood obesity and related metabolic disorders continue to rise globally, impacting

As biologics grow more complex, Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that cut risk and speed development. The post On the fast track to the clinic: early decisions in drug development appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

In recent years, the intersection of artificial intelligence and tourism has garnered considerable attention, bringing innovative solutions to a sector traditionally reliant on personal recommendations. In a pioneering study, Feng introduces a sophisticated tourism recommendation model that leverages a combination of intelligent genetic algorithms (IGA) and multi-source heterogeneous data. This approach stands to revolutionize the

In an era where sustainable agriculture stands at the forefront of global ecological and economic challenges, innovative frameworks to manage and leverage data are emerging as powerful catalysts for change. The latest breakthrough by researchers Gans Combe and S. Camaréna introduces a sophisticated valuation model intertwined with the concept of data sovereignty—a notion poised to

In the realm of pediatric cardiac imaging, the quest for optimal techniques that minimize radiation exposure while maximizing image quality has emerged as a principal concern for medical professionals and researchers alike. A recent study led by a team of experts, including Dang, Zhou, and Arguello Fletes, delves into this critical issue, particularly focusing on

In the realm of cancer treatment, recent breakthroughs have emerged that could significantly alter the course of therapy for gastric cancer patients. A pivotal study titled “Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up” sheds light on the efficacy and safety of combining Tislelizumab, a novel immunotherapeutic agent, with standard chemotherapy regimens.

In a groundbreaking study set to reshape our understanding of genetic malformations in livestock, researchers have identified critical genetic and epigenetic markers associated with umbilical hernia in pigs, specifically in the METTL21C gene. This study not only illuminates the roots of a condition that poses significant economic challenges within the pig farming industry but also

In a groundbreaking advancement poised to revolutionize optical technologies, a team of physicists has unveiled a new class of non-Hermitian systems that exploit three-dimensional (3D) chirality to achieve unprecedented control over light polarization. This innovative study, published recently in Light: Science & Applications, elucidates how these systems enable asymmetrical polarization switching and omni-polarizer functionality at

In recent years, the process of ferroptosis has garnered significant attention within the medical and scientific communities. As researchers delve into the underlying mechanisms of this unique form of cell death, its implications on various diseases become increasingly evident. One of the most pressing areas of interest is its association with sepsis, a life-threatening condition

In the realm of healthcare, innovation is crucial, especially within intensive care units (ICUs) where the stakes are incredibly high. Recent research conducted by Ge, WJ., Cao, ZM., Zhu, XY. et al. has shed light on the factors that significantly influence the innovative behaviors of ICU nurses. Through a rigorous multicenter cross-sectional study, the authors

Guest contributor Jennifer N. Perusini explains why psychiatry must embrace precision medicine. The post Precision psychiatry is the future of mental healthcare appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. The Danish pharma has dropped development of GEN1160, a company spokesperson confirmed to Fierce Biotech, halting a phase 1/2 trial of the asset.

After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech XenoTherapeutics.

Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Suzhou Puhe BioPharma and Beijing Youngen Technology.

At the center of the acquisition is Halda’s “hold and kill” bifunctional small molecule platform and a lead candidate in prostate cancer.

Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts.

Explore 10 gene therapy companies operating within the biotech industry, as each one hopes to develop their own novel candidates. The post 10 gene therapy companies you should know about appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The biotech will use the funds to extend its clinical ambitions for its pipeline of DNA-damage-response-inhibiting cancer prospects.

After touting an impressive 1 billion-euro-plus fundraising haul back in March, European venture capital firm Sofinnova Partners is back in the spotlight with the close of another flagship fund.

Labiotech sat down with Jennifer Altomonte, co-founder of the BioEurope Startup Spotlight finalist, Fusix Biotech, who discussed Fusix’s cancer platform technology. The post Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts.

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market.

Neuro biotech Ovid Therapeutics' C-suite is metamorphosing, with co-founder and longtime CEO Jeremy Levin, Ph.D., set to give up the reins. Levin will step down Jan. 1 to make room for Meg Alexander, who will become Ovid’s chief exec after first joining the company in 2021.

European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative biotechs.

From plastic-eating plants to AI-guided therapies, iGEM 2025 reveals the innovations defining the future of synthetic biology. The post iGEM Jamboree: leap into the synthetic biology future appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to swoop in and snatch the startup from under Pfizer’s nose.

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash.

Third Arc Bio will use Adagene’s precision antibody masking platform—dubbed Safebody—to create new CD3 T-cell engagers against tumor-associated antigens.

Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid off.

Discover how biosimilars in Europe expand access, cut costs, and strengthen healthcare systems for a more sustainable future. The post Biosimilars: a vital remedy for Europe’s healthcare challenges appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 19 promising Swiss biotech companies. The post Swiss biotech going strong in 2025: 19 companies to put on your radar appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

AbbVie is ending an 11-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat.

The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research. The post New cancer cell discovery sheds light on childhood blood cancer   appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

One in four safety-related failures are due to central nervous system (CNS) toxicity.

Australian biotechs share lessons from BIO-Europe on building global partnerships and driving growth beyond their domestic market. The post BIO-Europe partnering: Australian biotech companies share their experiences appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

October saw a wave of M&As and biotech deals in various therapeutic fields, but particularly for therapies addressing autoimmune conditions. The post Top biotech deals in October 2025  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Llusern’s Lodestar DX aims to improve urinary tract infection diagnostics. It has created a test that detects pathogens in just 35 minutes, no lab required. The post Next‑generation UTI diagnostics: delivering results in just 35 minutes appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and obesity. The post Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Long regarded as one of Japan’s best-kept biotech secrets, JCR Pharmaceuticals, now in its 50th year, is stepping onto the global stage. With a proven platform for delivering therapeutics across the blood-brain barrier (BBB), a growing pipeline, and global partnerships with major pharmaceutical players, JCR is redefining what it means to innovate across barriers and borders.

Company leaders at Bayer discuss how integrating R&D and commercialization is transforming drug development for greater impact

UZEDY (risperidone) Teva Patent: 10,736,965 Expiration: Jan 12, 2025 See More … For more information on how DrugPatentWatch can help Source

In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. From mergers and acquisitions Source

The Art of Pharmaceutical Negotiations: What You Need to Know As a professional in the pharmaceutical industry, you're likely no stranger to the complexities of negotiations. From securing lucrative deals with manufacturers to navigating the intricacie... Source

The Generic Drug Revolution: Setting the Stage Before we dive into the nitty-gritty, let’s take a moment to appreciate the Source

Revolutionizing Generic Drug Development: Lessons from the Pioneers As the pharmaceutical industry continues to evolve, the quest for innovative approaches to generic drug development has never been more pressing. With the cost of prescription medicati... Source

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. Source

Unlocking the Potential of Biosimilars: A Closer Look at Market Dynamics Across Patient Populations As the biosimilar market continues to grow, it's essential to understand the nuances of how these treatments interact with different patient populations... Source

Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Source

Navigating the Complex World of Contract Development and Manufacturing: Top Tips for Startups As a startup in the pharmaceutical industry, you're likely no stranger to navigating complex landscapes. From regulatory hurdles to clinical trials, every ste... Source

A robust patent strategy can make or break a company’s success. With billions of dollars invested in research and development, Source

Maximizing Your Pharmaceutical Company's Potential: A Proven Approach to Optimizing Your Drug Patent Strategy As a pharmaceutical executive, you understand the importance of protecting your company's intellectual property and staying ahead of the compe... Source

Generic drugs play a crucial role in providing affordable medication options to patients. However, many individuals still harbor misconceptions and Source

Breaking Down Barriers: Educating Patients About Generic Drugs As healthcare professionals, we've all been there - a patient comes to us with concerns about a new medication, only to reveal that they're hesitant to switch to a generic alternative. It's... Source

TRILIPIX (choline fenofibrate) Abbvie Patent: 7,259,186 Expiration: Jan 7, 2025 See More … For more information on how DrugPatentWatch can Source

The biopharmaceutical industry is witnessing unprecedented growth, with the Contract Development and Manufacturing Organization (CDMO) market expected to reach $289.64 Source

Unlock the Full Potential of Your CDMO Partnership As a pharmaceutical executive, you know that partnering with a Contract Development and Manufacturing Organization (CDMO) can be a game-changer for your business. But have you ever wondered how to ensu... Source

Is Vascepa Effective for Reducing Heart Disease Risk? Heart disease is a leading cause of death worldwide, and reducing... https://www.Drugchatter.com/chat/45909/is-vascepa-effective-for-reducing-heart-disease-risk/ Source

Unlock the Secrets to a Thriving Generic Drug Development Strategy As a seasoned professional in the pharmaceutical industry, you know that developing a successful generic drug is no easy feat. With the ever-changing landscape of patent laws, regulator... Source

The Unseen Heroes of Affordable Healthcare: The Power of Generics As we navigate the complexities of the healthcare system, it's easy to overlook the unsung heroes that make a significant difference in our lives: generic medicines. These affordable alt... Source

The Hidden Power of Effective Patent Management: Unlocking Your Pharmaceutical Business's Full Potential As a pharmaceutical professional, you're likely no stranger to the complex world of drug patents. With the average cost of developing a new medicat... Source

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.